Sedivention banked €2.9M in a Seed round led by bmp Ventures. The investment includes participation from the IBG Risikokapitalfonds IV and several private business angels from the medical sector.
The German medtech startup is developing a medical device designed to treat obesity through a single, minimally invasive procedure. The technology uses a cryogastric ablation catheter to freeze the vagus nerve in the stomach. By reducing the nerve's activity, the device aims to decrease hunger signals and increase the feeling of satiety, offering a procedural alternative to daily pharmaceutical interventions.
Founded by Dr. Bodo G. Ischebeck, a specialist in visceral surgery, the company plans to use the capital to complete its clinical pilot study and advance the technical development of its catheter system. The approach targets the growing demand for metabolic treatments that avoid the long-term dependency and side effects associated with weight-loss drugs.
This raise reflects a broader trend in European medtech where hardware-based interventions are seeking to capture market share from the rapidly expanding GLP-1 pharmaceutical sector.
Originally reported by Tech Funding News.